sunvozertinib
dizal pharmaceuticals
['sunvozertinib']
#asco23 wu-kong6: phase 2 sunvozertinib for egfr exon20ins
1 orr 60.8% (48.5% in pts w/ brain mets)
2 orr consistent across loop location
3 median dor not reached after median f/u at 7.1 mos for responders a new promising drug for egfr exon20ins
more will be 
Hematology/Medical Oncology Fellow @RoswellPark
Thoracic Oncology Researcher
Future Asst Professor @UW & @FredHutch
Retweet ≠ endorsement
Views are my own